Outlook Therapeutics gets UK MHRA approval for LYTENAVA (bevacizumab gamma) for wet AMD

Outlook Therapeutics, Inc.

UK MHRA granted Marketing Authorization for LYTENAVA (bevacizumab gamma) to treat wet age-related macular degeneration.
LYTENAVA is the first and only authorized ophthalmic bevacizumab formulation for wet AMD in the EU and UK.
Approval leveraged EMA positive opinion under the new International Recognition Procedure.
This regulatory milestone supports Outlook's commercial strategy in the UK market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.